<SEC-DOCUMENT>0001214659-17-002568.txt : 20170417
<SEC-HEADER>0001214659-17-002568.hdr.sgml : 20170417
<ACCEPTANCE-DATETIME>20170417100026
ACCESSION NUMBER:		0001214659-17-002568
CONFORMED SUBMISSION TYPE:	PX14A6G
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20170417
DATE AS OF CHANGE:		20170417
EFFECTIVENESS DATE:		20170417

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Merck & Co., Inc.
		CENTRAL INDEX KEY:			0000310158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				221918501
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		PX14A6G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-06571
		FILM NUMBER:		17763711

	BUSINESS ADDRESS:	
		STREET 1:		2000 GALLOPING HILL ROAD
		CITY:			KENILWORTH
		STATE:			NJ
		ZIP:			07033
		BUSINESS PHONE:		908-740-4000

	MAIL ADDRESS:	
		STREET 1:		2000 GALLOPING HILL ROAD
		CITY:			KENILWORTH
		STATE:			NJ
		ZIP:			07033

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Merck & Co. Inc.
		DATE OF NAME CHANGE:	20091103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SCHERING PLOUGH CORP
		DATE OF NAME CHANGE:	19920703

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TRILLIUM ASSET MANAGEMENT, LLC
		CENTRAL INDEX KEY:			0000884541
		IRS NUMBER:				042549211
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		PX14A6G

	BUSINESS ADDRESS:	
		STREET 1:		TWO FINANCIAL CENTER
		STREET 2:		60 SOUTH STREET, SUITE 1100
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02111
		BUSINESS PHONE:		617-423-6655

	MAIL ADDRESS:	
		STREET 1:		TWO FINANCIAL CENTER
		STREET 2:		60 SOUTH STREET, SUITE 1100
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02111

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TRILLIUM ASSET MANAGEMENT CORP
		DATE OF NAME CHANGE:	20000519

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FRANKLIN RESEARCH & DEVELOPMENT CORP
		DATE OF NAME CHANGE:	19990326
</SEC-HEADER>
<DOCUMENT>
<TYPE>PX14A6G
<SEQUENCE>1
<FILENAME>j411171px14a6g.htm
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Securex Filings LLC
    Document created using EDGARfilings PROfile 4.2.1.0
    Copyright 1995 - 2017 Summit Financial Printing, LLC.  All rights reserved.-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" bgcolor="#ffffff" text="#000000">
<div><img src="trilliumlogo.jpg"></div>

<div>&#160;</div>

<div>&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center"><u>Open Letter Regarding Trillium Asset Management&#8217;s Shareholder Proposal at</u></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center"><u>Merck &amp; Co. Regarding Opportunities to Strengthen Board Oversight of Product Manufacturing Quality and Safety</u></div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">April 17, 2017</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Dear Merck &amp; Co. shareholders and proxy advisory services,</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Trillium Asset Management, has filed a shareholder proposal (Proposal 8 on the company proxy materials) at Merck &amp; Co. asking the Board to:</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">issue a report (at reasonable cost, in a reasonable time and excluding confidential information) evaluating the merits and feasibility of Merck (1) strengthening Board expertise in pharmaceutical manufacturing and product quality and safety, (2) adopting an independent board chair leadership structure, and (3) any other related governance improvements the Board wishes to consider.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;FONT-FAMILY: 'Times New Roman', serif">1</sup></div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Stated briefly, given the extraordinarily high risks for Merck with respect to manufacturing product quality and safety, it is common sense for the Board to take a reasonable amount of time to evaluate and report out on whether they have the right governance in place to oversee these significant and material risks. Specifically, whether the board is developing and selecting the skills, expertise, and experience it needs to correctly evaluate and oversee manufacturing product safety and quality. Unfortunately, experience in product quality, safety or pharmaceutical manufacturing is not identified for any of the company&#8217;s board members<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">.</font></div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Product manufacturing safety and quality is a high risk issue area for Merck &amp; Co.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table id="zff10e813947743c6b3c8d533f83429d7" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; WIDTH: 18pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Merck develops and globally sells biopharmaceuticals manufactured in high production volumes at numerous facilities in the United States, Puerto Rico, Japan, Singapore, South Africa, Western Europe, Central and South America, and Asia overseen from its manufacturing headquarters in New Jersey. Therefore, the company is exposed to many product safety and quality related risks, including operating, regulatory adherence, financial, reputational, and litigation.</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left">
<table id="z1b262c51eabf49e8a30e45330617d888" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; WIDTH: 18pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">MSCI&#8217;s ESG Manager concludes that Merck has a high risk exposure on product safety and quality, but lacks the strong product safety and quality management policies and practices necessary for its level of risk &#8211; making it a laggard compared to peers.</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left">&#160;</div>

<div style="TEXT-ALIGN: left">
<hr style="BORDER-TOP: 0px; HEIGHT: 1px; BORDER-RIGHT: 0px; WIDTH: 2in; BORDER-BOTTOM: 0px; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; BORDER-LEFT: 0px; BACKGROUND-COLOR: #000000; MARGIN-RIGHT: auto" align="left" noshade="noshade">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;FONT-FAMILY: 'Times New Roman', serif">1</sup>&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #0000ff"><u>http://www.trilliuminvest.com/shareholder-proposal/merck-product-safety-quality-2017/</u></font></div>
</div>

<div style="TEXT-ALIGN: left">&#160;</div>

<div style="TEXT-ALIGN: left">&#160;</div>

<div style="TEXT-ALIGN: left"><img src="trilliumfooter.jpg"></div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="TEXT-ALIGN: left">&#160;</div>

<div style="TEXT-ALIGN: left">
<table id="zed7c40ec779642b19cae5ba677a68896" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; WIDTH: 18pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">The United States Food and Drug Administration (FDA) and increasingly its international counterparts are prioritizing that biopharma manufacturers produce more consistent and higher quality outcomes in their manufacturing production lots. To provide better regulatory oversight in this area, the FDA formed an Office of Pharmaceutical Quality (OPQ) in 2014 and developed a Pharma Quality System (PQS) with detailed guidelines in the areas of Quality, Production, Laboratory, Facilities Management, Materials, and Packaging/Labeling. Furthermore, the FDA&#8217;s PQS notes that biopharma company management is responsible for a company&#8217;s 1) leadership and commitment to quality, 2) quality planning, including addressing complaints, 3) resource management, 4) internal communication, 5) management review of manufacturing and quality, and 6) oversight of outsourced activities.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;FONT-FAMILY: 'Times New Roman', serif">2</sup>&#160; Regulators also consider biopharma companies manufacturing site inspections with new drug approvals, which are key to helping the company achieve sustainable revenue and cash flow growth. As a result, it is important for biopharma companies&#8217; Boards to include 1) specific committee oversight for manufacturing product quality and safety and 2) multiple members with biopharma manufacturing skills and experience to ensure the company is a leader in this key operating area and minimize the risks noted earlier.</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left">
<table id="z48a643e8d4d143d39e9ad84703323f01" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; WIDTH: 18pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Merck received a warning letter in 2016, a Form 483 in 2015, and six Form 483s in 2014, indicating potential manufacturing site and emerging quality issues in the company&#8217;s operations.</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left">
<table id="zb595fefb112b481b82ab82592ff89a4a" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; WIDTH: 18pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">An October 2016 PWC survey reported that 85% of board members in the pharma/life sciences industry feel that regulatory compliance risks pose the greatest oversight challenges to their boards.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;FONT-FAMILY: 'Times New Roman', serif">3</sup></div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left">
<table id="z23f4401e4e244305a1a6b58c627cfdd8" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; WIDTH: 18pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">As Merck&#8217;s reputation with institutional investors and sell side Pharma Industry Research Analysts improves, particularly with the future commercial potential of Keytruda, pressure may build over time for Merck&#8217;s management to meet operating margin, cash flow, and earnings metrics that support short-term shareholder return generation. We fear this pressure may potentially incentivize Merck&#8217;s management to misspend on necessary operating expenses and capital expenditures to support leading manufacturing product quality assurance and controls. Moreover, we know that the company&#8217;s CEO and Named Executive Officers total compensation is significantly tied to cumulative, three-year Operating Cash Flow and relative total shareholder return performance vs. its peer group, as well as revenues and EPS.</div>
</td>
</tr>
</table>
</div>

<div>&#160;</div>

<div>
<hr style="BORDER-TOP: 0px; HEIGHT: 1px; BORDER-RIGHT: 0px; WIDTH: 2in; BORDER-BOTTOM: 0px; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; BORDER-LEFT: 0px; BACKGROUND-COLOR: #000000; MARGIN-RIGHT: auto" align="left" noshade="noshade">
<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;FONT-FAMILY: 'Times New Roman', serif">2</sup> The Pharmaceutical Quality System (PQS) presentation slides by Robert Iser, Scientific Advisor, Office of Process and Facilities, Office of Pharmaceutical Quality, FDA&#8217;s &#8220;Regulatory Education for Industry: Focus on CGMPs &amp; FDA Inspections&#8221; Conference, July 15-16, 2015.

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;FONT-FAMILY: 'Times New Roman', serif">3</sup>&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #0000ff"><u>http://www.pwc.com/us/en/corporate-governance/annual-corporate-directors-survey/board-composition-and-diversity.html</u></font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">2</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">The Board&#8217;s primary assertion in its statement of opposition to this shareholder proposal is that the independence of the members of the board and their commitment to product quality and safety provides effective oversight of the business. However, in Merck&#8217;s 2017 proxy describing the &#8220;Experience and Qualifications of Particular Relevance to Merck&#8221; of its director nominees &#8211; experience in quality, safety or pharmaceutical manufacturing is not identified for any nominees. In contrast Eli Lilly, Bristol Myers Squib, and Johnson and Johnson proxies each have one director with expressly identified experience in manufacturing<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">.</font></div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Merck&#8217;s 2017 proxy highlights a number of areas of expertise and qualification for being nominated to the board including finance, management, investment banking, operational, technology, marketing, communications, science, medical, and international business. We do not doubt that these are important and necessary areas of expertise. However, we are concerned that in the midst of all of these qualifications, that product safety, quality, and manufacturing are not identified.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">As such, the disagreement really comes down to whether the board should re-examine if it has the right expertise on the board to oversee product quality and safety. There is no debate over whether manufacturing product quality and safety is a particularly high-risk issue for Merck. There is no debate over whether product quality and safety is of the utmost importance to the Board and is part of its responsibilities to oversee. The question that is raised is whether the Board should take a reasonable amount of time to evaluate the merits of strengthening Board expertise in manufacturing product quality and safety.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Can the Board effectively oversee operational and executive personnel if they do not themselves have individuals on the board with expertise in biopharmaceutical product manufacturing, quality, and safety? Would the board ask better questions of management and/or external experts/consultants with board members with expertise? Will they be better able to discern the wheat from the chaff in the answers and reports they get from operational, manufacturing, and executive personnel with expertise?&#160; Will they be better able to guide and advise the company on product quality and safety with expertise on the board?&#160; Would the board&#8217;s Compensation and Benefits Committee members be better prepared to ensure better alignment of CEO and NEO incentive compensation with the company&#8217;s important and relevant manufacturing product quality and safety metrics?</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">We respectfully believe the answer is, yes of course. How could that not be the case? In today&#8217;s high risk environment this is an area where we believe the Board should make sure it is going above and beyond to demonstrate its command of manufacturing product quality and safety oversight.</div>

<div>&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">3</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div>&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">We believe the requirement for deep expertise in this key business area is similar to Merck existing priority to seek Board members with skills and experience in 1) medicine, science, research, and development, 2) regulatory affairs, 3) finance and accounting, and 4) talent management. This is of course, good governance and as volumes of research have shown, improving governance is linked to reduced business risk and lower valuation discount rates (increased forward valuation multiples)<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">.</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;FONT-FAMILY: 'Times New Roman', serif">4</sup></div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">For these reasons, we respectfully urge you to support Proposal 8 on the company proxy ballot.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Sincerely,</div>

<div><br>
<img src="kronsig.jpg"></div>

<div>&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Jonas Kron</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Senior Vice President</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #0000ff; TEXT-ALIGN: left"><u>jkron@trilliuminvest.com</u></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">503-894-7551</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">IMPORTANT NOTICE:&#160; The cost of this communication is being borne entirely by Trillium Asset Management, LLC.&#160; Trillium is NOT asking for your proxy card and is not providing investment advice.&#160; We will not accept proxy cards, and any proxy cards received will be returned.&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left">The information provided in this material should not be considered a recommendation to buy or sell any of the securities mentioned. It should not be assumed that investments in such securities have been or will be profitable. The securities mentioned have been selected by the authors on an objective basis to illustrate views expressed in the commentary and do not represent all of the securities purchased, sold or recommended for advisory clients. A complete list of companies that are on Trillium&#8217;s &#8216;Buy List&#8217; is available on request. The information contained herein has been prepared from sources believed reliable but is not guaranteed by us as to its timeliness or accuracy, and is not a complete summary or statement of all available data. This piece is for informational purposes and should not be construed as a research report.<br>
<br>
<hr style="BORDER-TOP: 0px; HEIGHT: 1px; BORDER-RIGHT: 0px; WIDTH: 2in; BORDER-BOTTOM: 0px; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; BORDER-LEFT: 0px; BACKGROUND-COLOR: #000000; MARGIN-RIGHT: auto" align="left" noshade="noshade">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;FONT-FAMILY: 'Times New Roman', serif">4</sup> E.g. El Ghoul, Sadok; Guedhami, Omrane; Kwok, Chuck C. Y.; Mishra, Dev R.;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>Journal of Banking and Finance</u></font>, 9/2011. Bebchuk, Lucian; Cohen, Alma; Ferrell, Allen;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>The Review of Financial Studies</u></font>, 9/2004. Regalli, Massimo; Soana, Maria-Gaia; Working Paper, 12/26/2010. <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#160;</font>&#8220;Learning and the disappearing association between governance and returns&#8221;, Bebchuk, Lucian; Shoen, Alma; Wang, Charles C.Y.;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>&#160;</u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>Journal of Financial Economics</u></font>, 12/2011. &#8220;The AGR Anomaly: Corporate Governance and the Systematic Mispricing of US Stocks&#8221;, Torous, Walter and Allred, Micah; Working Paper, UCLA Anderson School of Management, 5/19/2010. &#8220;Corporate governance and valuation: an integrated approach&#8221;, QSG Equity Research, 6/2010. &#8220;Corporate governance and firm value: International evidence&#8221;, Ammann, Manuel; Oesch, David; Schmid, Markus;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>Journal of Empirical Finance,</u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#160;</font>10/20/2010.</div>

<br>
</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">4</font></div>

<div>
<hr style="BORDER-TOP: medium none; HEIGHT: 2px; BORDER-RIGHT: medium none; BORDER-BOTTOM: medium none; COLOR: #000000; TEXT-ALIGN: center; MARGIN-LEFT: auto; BORDER-LEFT: medium none; BACKGROUND-COLOR: #000000; MARGIN-RIGHT: auto" align="center" noshade="noshade">
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>kronsig.jpg
<TEXT>
begin 644 kronsig.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (   $Q  (    0    3@
M      !@     0   &     !<&%I;G0N;F5T(#0N,"XU /_; $,  @$! @$!
M @(" @(" @(#!0,# P,#!@0$ P4'!@<'!P8'!P@)"PD(" H(!P<*#0H*"PP,
M# P'"0X/#0P."PP,#/_; $,! @(" P,#!@,#!@P(!P@,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( "L
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
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1BB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>trilliumfooter.jpg
<TEXT>
begin 644 trilliumfooter.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (   $Q  (    0    3@
M      !@     0   &     !<&%I;G0N;F5T(#0N,"XU /_; $,  @$! @$!
M @(" @(" @(#!0,# P,#!@0$ P4'!@<'!P8'!P@)"PD(" H(!P<*#0H*"PP,
M# P'"0X/#0P."PP,#/_; $,! @(" P,#!@,#!@P(!P@,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( "$"
M:0,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_
MQ "U$  " 0,# @0#!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q  ? 0 # 0$! 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($
M! ,$!P4$!  ! G<  0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
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MP/\ PTSX2_YZ>(O_  FM2_\ C%'_  TSX2_YZ>(O_":U+_XQ7?447069P/\
MPTSX2_YZ>(O_  FM2_\ C%'_  TSX2_YZ>(O_":U+_XQ7?447069P/\ PTSX
M2_YZ>(O_  FM2_\ C%'_  TSX2_YZ>(O_":U+_XQ7?447069P/\ PTSX2_YZ
M>(O_  FM2_\ C%'_  TSX2_YZ>(O_":U+_XQ7?447069P/\ PTSX2_YZ>(O_
M  FM2_\ C%'_  TSX2_YZ>(O_":U+_XQ7?447069P/\ PTSX2_YZ>(O_  FM
M2_\ C%'_  TSX2_YZ>(O_":U+_XQ7?447069P/\ PTSX2_YZ>(O_  FM2_\
MC%'_  TSX2_YZ>(O_":U+_XQ7?447069P/\ PTSX2_YZ>(O_  FM2_\ C%'_
M  TSX2_YZ>(O_":U+_XQ7?447069P/\ PTSX2_YZ>(O_  FM2_\ C%'_  TS
MX2_YZ>(O_":U+_XQ7?447069P/\ PTSX2_YZ>(O_  FM2_\ C%'_  TSX2_Y
MZ>(O_":U+_XQ7?447069P/\ PTSX2_YZ>(O_  FM2_\ C%'_  TSX2_YZ>(O
M_":U+_XQ7?447069P/\ PTSX2_YZ>(O_  FM2_\ C%'_  TSX2_YZ>(O_":U
M+_XQ7?447069P/\ PTSX2_YZ>(O_  FM2_\ C%'_  TSX2_YZ>(O_":U+_XQ
M7?447069P/\ PTSX2_YZ>(O_  FM2_\ C%'_  TSX2_YZ>(O_":U+_XQ7?44
M7069P/\ PTSX2_YZ>(O_  FM2_\ C%'_  TSX2_YZ>(O_":U+_XQ7?447069
MP/\ PTSX2_YZ>(O_  FM2_\ C%'_  TSX2_YZ>(O_":U+_XQ7?447069P/\
MPTSX2_YZ>(O_  FM2_\ C%'_  TSX2_YZ>(O_":U+_XQ7?447069P/\ PTSX
M2_YZ>(O_  FM2_\ C%'_  TSX2_YZ>(O_":U+_XQ7?447069P/\ PTSX2_YZ
M>(O_  FM2_\ C%'_  TSX2_YZ>(O_":U+_XQ7?447069P/\ PTSX2_YZ>(O_
M  FM2_\ C%'_  TSX2_YZ>(O_":U+_XQ7?447069P/\ PTSX2_YZ>(O_  FM
M2_\ C%'_  TSX2_YZ>(O_":U+_XQ7?447069P/\ PTSX2_YZ>(O_  FM2_\
MC%'_  TSX2_YZ>(O_":U+_XQ7?447069P/\ PTSX2_YZ>(O_  FM2_\ C%'_
M  TSX2_YZ>(O_":U+_XQ7?447069P/\ PTSX2_YZ>(O_  FM2_\ C%'_  TS
MX2_YZ>(O_":U+_XQ7?447069P/\ PTSX2_YZ>(O_  FM2_\ C%'_  TSX2_Y
MZ>(O_":U+_XQ7?447069P/\ PTSX2_YZ>(O_  FM2_\ C%'_  TSX2_YZ>(O
M_":U+_XQ7?447069P/\ PTSX2_YZ>(O_  FM2_\ C%'_  TSX2_YZ>(O_":U
M+_XQ7?447069P/\ PTSX2_YZ>(O_  FM2_\ C%'_  TSX2_YZ>(O_":U+_XQ
M7?447069P/\ PTSX2_YZ>(O_  FM2_\ C%'_  TSX2_YZ>(O_":U+_XQ7?44
M7069P/\ PTSX2_YZ>(O_  FM2_\ C%'_  TSX2_YZ>(O_":U+_XQ7?447069
MP/\ PTSX2_YZ>(O_  FM2_\ C%'_  TSX2_YZ>(O_":U+_XQ7?447069R?A/
MXV>'_&VM1Z?I[ZPUU(K,HN-%O;6/ &3EY8E0<=B>:ZRBBDP04444AGS[\8_V
MI/$G@+XE>+-,L)?"0M_#<-C);6%Y%,;_ %AK@'='$RR@;E('\!^\*V_%OQV\
M7)_PF.LZ%IV@R^'/ <GE:A%=&0WEZT<*3W(C8,$3RT< ;E;<P/2J7Q9_90U?
MXC_$'Q1?P:OH-KI?BRWM;:Y%UI?VJ[M%A1EW0N6 1B6)SVPI[5I>)OV9M8NK
MG7=.T;Q4NF^%_%S*^M6DMEYUR[>6D4QBEW@*9HT56+*<')YS@:WB9-2*&M_M
M+ZS<?%6ZT;3)O"5A:VCVAMK;6'E@NM<AF16,MO)N" #<0 5;)7!VYJ;4OC'X
MW\,?%_7M+U.Y\(#P_P"'=)/B"ZDBT^Y%RUH'D!C4F?;Y@5#\Q7;GM4_Q)_9D
MUCXCZO>V-UXFM'\(W]Q#<"RN-,$UWIX39NBMIMX\I6V'Y@N5W'&:ZC5/@I'K
M_P 4?$&M7\\4^EZ_X?70IK/:0Y7?(7);I@J^,4KQ':1R.F?'?QEI'_".7?B"
MP\.K8>,K">YT]+,2^=I\J6QN4CF+.1+N0,"4"@%>XP3S_P -/VP]?\7^$?#;
MW^G:/;:YJ'B+3]-OHXXY/)-G>1>=%-$"^58KE>2PW(W'8=3X>_9OUZ.XTR'7
M/%4&K:;X8L9[/18DL/(D!DA\D23MO;>R1DJ-H&<D\=*R6_8]O(=2^&5U;ZY!
M$_@F*TAU)?*;9J8MGW1%1GY2I>;DY_UGURTXBM(]$_:%^/WA?]ESX-:]X]\9
MWSZ=X;\.0K-=S)"TS_,ZQQHJ*"69Y'1 .F6&2!DBW\%OC+X;_:%^%>A^-?".
MI)JWAOQ%;"ZL;I4:/S$R0058!E96#*58 @J0>E-^-_P3\,_M&?"K6?!7C'3(
M]8\-Z_"(;RT=V02!75U(92"&5U5@0>"HJS\*/A5X?^!_PXT;PCX5TRWT;P]H
M%LMI8V<.2D,8[9)))))))))))))-:MX?ZOU]KS>7+RV^^]_E8S2Q'UCI[/E\
M^;FO]UK?.YY+-^TCXOTJ^\1ZU=6GAV;PCX<\6'PY<QQ03)?1Q%XD6XWF1D;#
M3("H09YQBK^M_M(Z[IOP"\=>*H[326U'PQK5QIMK&T4AADCCN(X@7&_<6VN2
M2& SCCM3(OV6]=O/$^LV][XCL?\ A#M9\2GQ+<Z?%9$W%S(&1DA>1FV^7NBC
M)^4YV]LY$^L_LM:IJ5SK&BQ^([>/P+XAU4ZO?Z>UCNO&=G21X5FW8$;.@.=N
MX D<]:QO$T7,8EW^U+XE@^)U_IL4GA*XM[3Q6GA^/2%AF&JW$+>7FX5O-*X4
M.Q)*8_=GI5C4/VR([.VOK 7OAW_A)K?QBV@QZ<2WF-:"]$'FE-^[?Y>6W9VY
M&=N.*V[W]E]Y9=5O8KK3EU>[\81>)[6[:W/F01H8,VY;J01&X]/GZ58O?V<;
MFZ\&7VEC4;59KOQ>WB42F$X5#>BY\KK][ VYZ9IWB.TA-)_:%O;W]I"X\+26
MUD/#<C3:;9WB ^=)J,,$,\L;'?C8(Y''W<[HR,UY[X7_ &TO%6L?#KQ7=W&E
M:&->L;VVM]&B2*58+I)KB2 -(#(6.TQ2$D%1\IZ8-=7H_P"QX^D7VE:VOB'4
M)/$=GK[:[<AKB0Z?,9)6,J)#G:C-$VS?@GCG@XJMX>_8TET>\\.SRZO;RR:-
M%J,<P6$A;DSM,T)Y/'E&=S[DY]*$XB]X]1^"OC:[^(_PC\.:_?1V\-YJ^GQ7
M<R0*RQ*SJ"0H)) ^I-<9\ _VYOAC^TU\4_''@OP9XB_M7Q%\/+K[)K-N;2:$
M1L&*,T;.H615D5XR5)PR9^ZR,W<?"+P/)\-/A=H'AZ:X2[ET:QBM'F12JRE%
M W 'H#7*_!;]CGX;_L\_$?QCXM\'>%[31?$'CVY^UZU=QR2.UT^YG. S$(I=
MG<A0 2WL -J+PWLZGM;\UERVM:]]>:^MK;6ZF558CGI^RMRW?->][6TM;2]]
M[]"G^T-\:==^&_C+PYI6CW7AC3X]7MKVXGNM:CD:)/(16504D3!;)'.>W%9/
MA'X_>,_C%96(\)Z;X>M;J#0;;6-274O-=3+<&3RK>/:RE=RQ.V]L@!EXKL?B
M5\#++XH?$SPOK.J0:9J&F:!%=)+87MJMPEPTJJ%;#94;2N>15+Q[\%]>F\9W
M&M^#/$5GX:N=4L(]-U&.;3_M,<B1EO*EC ==LD8=P,Y!!'3'/.FK&[3N>8>+
M/VU]:DCCOM'G\(Z;9/X6AU^.WU6*:6XO)V:16M8F25!NW)M'RGFNR\0_%+XB
M)\3O">CV1\(V5IXMLY+R..\L+F6XL?*AC>2-V6=58EF8 A1C SFH=1_8VL9;
M75+2&XLY+2;P@GAJP^TVX>6UE3S-MR2.^7!.W!R#78'X0WMSXX\":W<:A \G
MA/3Y[2Y0(<W3RPHA93V *D\^M4W'H)*74L_!GXG3^.OA+'XCU@6=HZSWRS&%
M62&..WNIH@WS$G[D8)YZYZ#BO,-!_:W\0:C\$O&^NW6F:59Z[H%O!J>GVS1N
M89;*Y17MVD D+%_OAL%1E1P*UM&_9^\<Z3\.=:\(CQ-H(T+4HKV. I82"Y@^
MTSO(Q+[\' DD &!SBJNO_L4QP66M6FA:]J"6FN:"-&E35+B2\:$I*CPNC,>$
M50Z[!@#=D>E)*-P][0S[[]K_ %^'PMI\RZ?HT6K1:5KCZK Z2.L%]I\!=57#
M@B-SAL')V.,-_$>Q^%GQ?\477C[2] \5P:'*_B#1O[9T^[TN*6%%"E \,B2.
MYW#S%(8,![5@_$+]CZZ\6?$G4M;LM:AL[35-!NM-FM9(F8"[GM#:FX&#P-@A
MR.I\OKTQTWPC^!VM^&O%EMKOBG7;/6+_ $K3!H^FPV=H;>"U@RI=SN9BTC;%
M&>  O?/ ^6V@)2N0?M9_MK_#?]B#P=I>O?$G7GT+3M9U!--M&CLI[MY96Y8[
M8D8A40,[,1T7 RQ56]0T_4(-5T^"[MI4FMKF-98I%Y5T89##V((->>?M-?LB
M?#O]L3PGIVB?$;PW;>)--TF^34;6*2:6$PS*"N0T;*<%692,X(/J 1Z';V$5
MGI\=K @@@AC$4:Q_*(U P /3 K:H\/["'L^;VEWS7MRVTY;=>][F5/ZQ[:?/
M;DTY;7O?6]^G:UCQOX+?M$:[\4/&T%O/)X4M;:66YBN]%9I8=:T@Q[]AD5VV
MR[BHR%5=H<$;@":R_!_[6>M^(M$^(]W/8:5$-!TBZUSPXRH^V^M8GN8U:4;R
M3EX%Y7;D/QC@U>NOV7/$NL:E;76J>+[/4;K08;I-&O3I@CU#?-')&C7%P&)9
M4$A^50 Y )QC%5#^Q/\ \(]I$5OH/B&_1I_#E[X<OAJ$\EU')#/!M3RE)Q$J
M38DVKP1D<9S67NFGO$_PN_:@UOQ?<>#-.U*TTBWUC5=4FL=7BA20+'']B>[M
MY807) =/+Y;=_&.".-3Q!\;];@_: U+PO%K'@O1M.TU+!T74X)6N]0\_?O2(
MK,J[AL 'RGEUZTEK^RW)IWQ8\$>)K;4X8E\.6,=KJ4 B.-0DBM9+>.5?[I"R
M,#G.0%':NKTKX-VL/Q>\2>*+Z.POQK$%C%:QRVX>2S:W$NY@S9QN,BGC'W?I
M2;70:4CS'X>_M3^)?$_Q-TO2YY/"=Y;:EKE]I4FGV4,R:C8PP&4"XD8RLNW]
MV,_(,[ABMSP#^TSJ7B[QYXOL)K*PATRRM+J[\/SJK;KY+69X)S(=YS^\"L-H
M7Y6IEC^RO>: NCWNG7VE1:WI.O7^K_:VMB#-'<B<"%B.3M\U>N1\O&,U6\-?
ML7Q^"3X<N-,\0:G+>:7:W-I>K>7$DUM.+B!EE:*,G$692), <XP>>:+Q$E(Q
M?A[^V7K?B/P3X>N-4L=%LM7N]?L+#455)! +*[A,T<\8+Y5MF5RQ89C;CL-P
M?'?XA2?"V?QQ%H&@2^'KS1[W5+6,.XN=-6.WDEMWGW2 3+(54,L04KNZGK5>
M[_8UN9[GX;2+K-NJ^#[>UMM5C,+&/54MVW18&?E(WS#)SQ)]<WQ^S+XH7P=>
M^%O^$VSX7@TN]TW3+1;,QR;9X7BC6Y<.?,2$,,8 W;03C&*=X@E+J9,W[4WB
M2\\3VNGP-X.TF8V&GWB6^KO-;OK1N(E>3[-)O"($)*_,'R< XZUU$'Q<\:>+
MO%>O/X:T?1K_ $/PSK*Z/=6\LC+?7; 1&:2)RZQ*(Q)G:V2VT\@X!Q_%/[*>
MO>+=(AT*Z\5V4_AF6VLX9[:XTL3W%H8(XT;[+(7'E>9L)S@E2<C-;DOP#U[2
M/&NHS:!XL.C>'=>U1-7U*T2TW71F 02+%,&&U)1&H;()'."<X";B/WC'OOVB
MO$EKI6J^+Q9Z"G@;1M9;2YXF$IU%XDN%MY+E7#>7PY)\LKDJI^;. =/]H7XV
M:Q\-?'/A?1]-O_"VDP:Y%=R3WNMQ2O%$850J!LECQNW$<Y[5!-^S-JAO[S2(
M_$<"> ]0U7^V;C3&L=]T\AF69[<3;@!"TB[L[=V"5_VJT/CQ\#]7^)GC#PYK
M.D7NA03:#'<QM#JMB;R"83*@^YD#(VGKZT+EN'O6./\ $_[6^OZ;\&O!6OV>
MBV+:OKUO/JM_:.&9(=/MU+321_.I#,#'LSD?/T-:GBC]I36M'^)-UX2MH-'N
M-4UR:PE\+S^3*T%U:3[C-), ^3Y2QR-E2H/R\#O7T?\ 8DM6BL+75_$.K7%E
MI>D/I< T^9[ R>=<2S3[@AP(B'1%BR5"QC.>,=-X,^ M]H6J_#J]O]1L[RY\
M#Z7=Z9)(L!5KL2+$D;C)^7:L9R.>7.*'RB2D>GC.!D@FBBBLS4**** "BBB@
M HHHH **** "BBB@ K@?VI?C?)^S7^SUXN\?)HEQXC7PEI[ZE+I\%PMO)/%'
M@R;78$ JFYL8.=N!R:[ZLCX@^!]/^)O@36O#>KPFXTK7[&;3KR/."\,L;1N,
M]B58\UK0E!5(NHKQNKKNNIE7C-TY*F[2L[/L^A\T1_\ !6[P+#\:[WPM=Z?=
MVNE6G@0^-EUPSJ;>X*V<5^]BJE1B86<GGY9E&T= 2*Y^V_X+$Z9I?@OQ/J/B
M/P!J_A_4]&\#Z1XYTS2GU&.>XUVVU*1888HRJ81Q-)%&V[D-)TX->6:]_P $
M+?$GB;]E#0/ M[\3K23Q5IGB=]0N_$ L),76EOI,>DM9K&7)5OLL$"9W%<(1
MCD8]X_:J_P"":\7[0/[1WPF\:Z9K=OH6F>!HH-.UO3_)=I-<TZVO;6^MK4.&
M&U4GM@QR#G<:^LE2R*,XQ4N9.]W[VG+K=?X]O+R/EHU,[E&4FK-6LO=UYM-?
M\&^^OF<WJO\ P6*TJ3X;:/XAT+P%JFO/??#>?XE7MK'J<43:=:0W"V\D!)7Y
MI _F\@ 'RB!DGC?3_@K=X%A^-E[X6N]/N[;2K3P(WC9=<,ZFWN"MG%?O8JI4
M8F%G)Y^691M'0$BG?LL_\$QM/^!6H?%^WUS5X?$/A_XAQW&C:/8+"8SX?T.6
MYOKEK!6)Y'FW\QR/1?2O"M>_X(6^)/$_[*'A_P #7OQ.M)?%>F>)WU"[\0"P
MDQ=:6^DQZ2UH(RY*M]E@@3.XKA",<C!3I9%*I*$I.,5HG[W57O;^[\+[WOJ$
MZF>1A&<4F^J]WH[6O_>W7:UM#T_]N3_@H#\1_AM_P3>\-?%WP-X)DTW5O%\6
MG7,@N[RVG/AV"[DB,3.CX$KR+(J *IV-)EAA35WXZ_\ !3'6?AMXUT'X<ZG\
M'?&K>,O%?A/^W[RRTG5+:XET&$W#P3M)-&&C AC5I?,4LI.U<9-=1^V%^Q7X
MW_:;_9Z^(GP^MO%V@:=I.HG29/!L$FG,%T@V31R/%<NIW2++)$N& RBGHV,&
M/2/V*O'/BKX]Z=\2O&GB;PW-XBD^&-SX'U2#2[.5+9[N:Y:8W$1<Y$0! VD;
MB1GCI6-"IEGL$ZD8W3F[)ROJHN";ZI.Z?FO-M[5X9E[9JG*5FH+:-M')2:71
MM6:\GY)+XU\7?M.:_??#?P!J'A3Q5X_M-&U+]GSQIK<(UC61=:B]U!#,8;B>
M6)(TDG1ERKA%(P,=*],^'O[=%K\!SX+\3Z_)\0/$^NZ+^RYH_C*_LVUN-='U
M$-=6\;RF%HC)]O:1CF<R%3&2NS/S5U=A_P $>-=L_AAX-\/GQMI+2^%_A5XA
M^'<DWV&3;/-J:2JER!NX2/S!E3R<<$5IZS_P2%O?%4=O;:AXQLTM$_9_M?@R
MY@LW\P7<$\<RZ@,M@Q;HQ^[/)Z;A7K5<=E,TH2DN6[OH[VYGUM?9GDTL%FL'
MSQB^:RMJK7Y8]+VW3/2/&7_!2G2_!WC/6]&D\*ZA/)HOPE'Q8:1;Q%$L!E:/
M[&!MXDRN=_3VKSOPG_P5E\;^-/%WAWP]:? +78]<^('A7_A*_"%O)XDL=FH6
MRY,AN) =L ";7 .6(900K' I>#?^"8/Q/UK4_%FL>/OB!X/U'5]?^$<GPKLT
MTG2)K>"QB#JT5PY=R9&)WL^ O,F% "C/IGPZ_8!U/P1\:/@KXJD\1V%Q#\*O
MA_+X,N+=;9U:_E>.)//0YPJCRR=IR>>M>7*.44HM:3=GUG:ZC==MY63\MK;G
MJ1EFU62>L%==(7LY)/OM&[7XWV/-?!W_  4,\._'?XJ_ WQO:V7C[2I_$?A+
MQ/J7]BQZK#%IBO8+MN([J+RV,[AXV\J170*#DJ<[0WPE_P %HKSQ!I>D:E=_
M!S7=.L/%G@G4O&GAS_B=6\TNJ1Z>K-<0E44^4Q5<H6Z@KD MA9O@K_P22UOX
M51_#!9_&6E7G_"O]!\4Z/-LLI%^V-K#NR.N6^41;N0<[L<8KIO@1_P $R=0^
M%'BCX 7FH^(])U>S^#OA+5?#-_;?8FVZQ]L4+O4,2%0 $%6!R#6U>>2JZ7O)
M<R6LMDZC2Z;^XM>C];8T(YP[-^ZW:^D=VJ:;Z[>^].WI?4B_X*Q^"0K7LVE:
MBN@V'PNA^*&IZC%,DJV<,T@CAL%0<R7#MNQG:ORCGGCSVR_X+=Z5HWPZ\?ZI
MXE\#MI^M>$_#ECXJT_2]-U^UU3^T[*\N5MD\R:+Y+>2&:2-9E?E V0&&,R_L
M[?\ !%O3_A#^S;\:?A]K/B^?6W^)]NVC:9J+0L[Z#I<0E:Q@"LV7:*69W8!@
MK@(N%"U6^$/_  2W^('@GX8>.K62\^ 7A?Q1K.@P>'])F\-?#JU2TGACF62<
MZAYB"2<70CC5TR40C>%<J!1&ED2<TG=*4;-N2NM+O1/^\GH]$FM=R53/&H-J
MS:E=)1=GK9=/)K5:MIZ;8O[17_!4SXQZ)\"O!GB'PM\*[*WGUWQU:>')]0L_
M$FG:II]["[PF.*VD+ %[G?)&)&7;"86+XW(:^L?VAOVJH?V7OV2-4^*?B_P_
M?6,FC:=;W5YH<5S%/<17,SQQ+:B53Y;-YTJIO4E>XR*^1-#_ ."-/C3PW^S;
MXBTW2/$G@/P[XWU/QYI?CO3M+TNRNT\*Z3-8_*EO&DC-,%D!9V;')"+C W5[
MY^T)^R!\1/VM/V;?B'X \=>,_#@B\6:-I":5_9^END>DZG:E9[F5B6#2PRW,
M<3*IP412.2:RQ<,JE.E&FXJ$9^\US*3BW'NWLF[:]';SUPD\TC"K*HI.;A[J
M?+RJ24NR6[2Z==?+G=0_X*7^*-"T+3_#^I?!W7K'XQ:YXD/AW1_"DM_&MMJ8
M%M]J>]COF41FWCASO(!967&.<U!K?_!6NVTSX*V6O0_#3Q%<^,/^%@_\*TU+
MPD=2M8[K3]7PQV"XR8)8S\F) P0[_O  FJ>N?L,_'3QW!H/C[Q'\3_"&H?&7
MP7X@EUGPS$ND2+X:TNVDM&M)K C(N72=#O>0G<K;0H(7++:_\$M-5?P%X;6]
M\7:=<^,6^+,7Q5\4:@ED\=IJ%PKONMK:+<3$@C\M5W,QRK$]< 4,H27/RWOK
M9SWUNM;>Y:UG\7-?5K4'/-FWR<UK:74-M+-VO[][W7PVMHF<_KO_  60\1>#
M_"_CG5-8^!^NVUO\)-?CTCQT\6O6DJ:5%-*B0R6^2#<LPD5BJA0H'+ $$?=%
MG>1ZA9PW$+;X9T$B-@C<I&0<'VKX[^*W_!+_ %CXB_#G]I70XO%FFVLGQXUN
MQU6SE>S=ETE;<P920!OG+>4>1C&:^OM$T\Z3HMG:,P=K6!(BP& VU0,_I7EY
MJ\"X0>$23OK;FVY8/JWM)S6G1+U?I96L:IR6*;:LK7Y=^:2Z6^RHOU;]%:HH
MHKQ3V0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
<@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>trilliumlogo.jpg
<TEXT>
begin 644 trilliumlogo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (   $Q  (    0    3@
M      !@     0   &     !4&%I;G0N3D54('8U+C P /_; $,  0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( #,
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
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M_8_]L:1_:O\ 9WVG^S_[5TW[7Y/VZU\WQW_AX?\ L ?]'R_L>?\ B3/P5_\
MFVKYL_X*;?\ !*OP#_P4U_X4E_PG'Q7\8?##_A2?_"R?[+_X131-%UC^W/\
MA9'_  @/VW[?_:\D?V;^S?\ A K3[+]GSYW]H7/FX\J+/\#/[6W[*F@?LX_M
MT>/_ -DK1?%FL>)/#W@[XF>$_ EMXNU2QLK36;VT\16/AJ[FOY[&T9K&.XMF
MUV5(HHV,3B",N<LU?N7AKX;\%\>X)4:G%&;83B+#8+&9AFF6T,MC+#87"T,>
M\-2G2Q=:"IUW4H5,)5E"$Y3C.K.-OW;M^*>(OB)QCP-C'5APUE>*R#$XS"X#
M+,QK9C*.)Q6)K8*.(JPJX6E-U**IUH8JE&<X1C*-*$K^^N;_ $K/A_\ MD?L
MA_%GQ9IG@+X5_M4_LW_$SQSK2WSZ-X+^'_QQ^&/C+Q9JR:9I]UJVI/IGAWPY
MXHU+6+]=.TJQO=2OFM;.46FGV=U>7!CMK>61.;U3]OK]A30]3U'1-;_;4_9+
MT?6='O[S2]7TC5/VC?@[I^IZ7J>GW$EI?Z=J-A=^,H;JQO[&ZAEMKRSN8HKB
MVN(I(9HTD1E'Y<_L._\ ! CX2?L/_M-?#W]IGPM^T!\1O'.N?#VW\8V]GX8U
M_P +^&=-TK41XQ\$>(O!%RUS>:=,]Y$;*U\137T B4B2XMHHY,1NYK^/'PS^
MSI_PUO\ \%./%'[.'_"8_P#"O_\ A;7[3_Q>\-?\)E_PCW_"5_\ "/[?%?C+
M4_MO_"._VYX;_M7/]G^1]F_MS3?]=YGG_N_+?IX;\-. >*<PX@EE?%^;U,@X
M>R+"YMC,RJ92Z->%:57,GC:3PM2DJLZ6&PF#H5X2HTZDZDZLZ<5*45$Y^(O$
M;COAG 9#',^$\IIY[G^=XG*\)EU/-%6HSI1I9<L'56*IU72A5Q&+Q=>A.-:I
M"%*-*%2349.1_I1_#']HS]GSXV-<+\&?CM\&OBXUHSK=+\,?B?X(\>M;-&J-
M(MP/"NN:J8619(V<2;2JNA; 89[_ ,9>-O!OPY\,:SXW^(7BWPSX$\%^';7[
M=X@\7>,M>TKPOX8T*R,L< O-9U_6[NQTK3+4SS0P_:+V[@A\V6./?O=0?\TW
M]O\ _84^,_\ P27_ &B?A]HMA\:;;7-9U31HOB5\+/BI\-KG6? ?B[3%TGQ!
M=Z9#=7NEPZG<ZMX0\06.H:='=VTNFZ]J^GRI(AL=:N+FUOX+/^LKXZ?';QE^
MTO\ \&[WB_XW_$,VTOCKQS^S)ITOBR]M$$46K:[H/CK3?"^HZ\8$2.*VG\07
M&B/K=U:6\:6MI=:A-;6BBVBB%<7$GA+EV6O@S-<CXE_MOACC#.\!D]'&_5'A
M<9AIXVO[-5(TIRM67)3Q+?M*>&G1K4?95:5Y<QV<.^*F8YE_K?E>=<._V+Q+
MPGDV.S>K@_K7UG"8B.#H^T<)5(1O1?/4PUN2IB(5:-;VM.K[MG^T_P */VC_
M -GCX\7&MVOP.^//P8^,UUX:AL;CQ';?"CXH^!_B)<:!;ZF]U'IL^MP^$-<U
MB32H=0DLKV.QEOE@2[>TNEMVD:WE"<D_[9O['T?CR7X6/^U=^S6GQ/A\5R^
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M_M6-^RI_P3X^+6H:1-;1^.?C1&OP$\#K.\BM!=?$/3M3@\5ZQ"D$\$_VG0O
M%CXKU'3)@9+:'7H]&%]#<6DLMO-R<9^%&-X<X[R?@_+\16QU#B!X#^R\=6I1
MC)K$5?JV+=>--JFG@JL*M:HHR7+A72G)IR;.K@_Q2PG$/!&;<6X^A1P5;(OK
MW]I8*C4E**>'I?6,+[&4TZC6,I3ITJ;E%WQ*J0BGRGW!X%_;/_8\^*/BK2?
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M,JM7+^)<XQ>)PM+!5YXJG2AFN*K)RH\BE!U()>S=3DC+FB^:SN?Z/U?YO_\
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$@#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
